Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis
-
- ODA Hitomi
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
-
- MORI Akihiro
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
-
- LEE Peter
- School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
-
- SAEKI Kaori
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
-
- ARAI Toshiro
- School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
-
- SAKO Toshinori
- School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1–7–1 Kyonancho, Musashino, Tokyo 180–8602, Japan
Bibliographic Information
- Other Title
-
- Internal Medicine : Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis
Search this article
Abstract
Sitagliptin is a dipeptidyl peptidase-4 inhibitor aimed at treating Type 2 diabetes mellitus (T2DM) and T1DM, by increasing blood levels of Glucagon-like peptide 1 (GLP-1) and insulin. The objective of this preliminary study is to characterize Sitagliptin’s ability for glycemic control, in healthy dogs under an oral glucose tolerance test (OGTT) environment. Overall, Sitagliptin did not result in any significant changes to temporal glucose and insulin concentrations. However, a ~55% increase in median total GLP-1 AUC0–120min was observed, as compared to baseline control in healthy dogs (n=5), thus indicating a similar mode of action of Sitagliptin between healthy dogs and humans. Future studies to validate the use of Sitagliptin with dogs suffering from insulin independent diabetes are warranted.
Journal
-
- Journal of Veterinary Medical Science
-
Journal of Veterinary Medical Science 76 (10), 1383-1387, 2014
JAPANESE SOCIETY OF VETERINARY SCIENCE
- Tweet
Details
-
- CRID
- 1390001206430826752
-
- NII Article ID
- 130004704116
-
- NII Book ID
- AA10796138
-
- ISSN
- 13477439
- 09167250
-
- NDL BIB ID
- 025876147
-
- PubMed
- 24931645
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed